Skip to main content

Advertisement

SpringerLink
Log in

Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan

  • Case Report
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Schweitzer N, Vogel A. Systemic therapy of cholangiocarcinoma: from chemotherapy to targeted therapies. Best Pract Res Clin Gastroenterol. 2015;29:345–53.

    Article  CAS  PubMed  Google Scholar 

  2. Goeppert B, Frauenschuh L, Renner M, Roessler S, Stenzinger A, Klauschen F, et al. BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. Mod Pathol. 2014;27:1028–34.

    Article  CAS  PubMed  Google Scholar 

  3. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373:726–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Protsenko SA, Semionova AI, Komarov YI, Aleksakhina SN, Ivantsov AO, Iyevleva AG, et al. BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment. Invest New Drugs. 2015;33:1136–43.

    Article  CAS  PubMed  Google Scholar 

  5. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet. 2012;379:1893–901.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483:100–3.

    Article  CAS  PubMed  Google Scholar 

  7. Yaeger R, Cercek A, O’Reilly EM, Reidy DL, Kemeny N, Wolinsky T, et al. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients. Clin Cancer Res. 2015;21:1313–20.

    Article  CAS  PubMed  Google Scholar 

  8. Sanz-Altamira PM, O’Reilly E, Stuart KE, Raeburn L, Steger C, Kemeny NE, et al. A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma. Ann Oncol. 2001;12:501–4.

    Article  CAS  PubMed  Google Scholar 

  9. Ole Larsen F, Taksony Solyom Hoegdall D, Hoegdall E, Nielsen D. Gemcitabine, capecitabine and oxaliplatin with or without cetuximab in advanced biliary tract carcinoma. Acta Oncol. 2015;1–4.

  10. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337–45.

    Article  CAS  PubMed  Google Scholar 

  11. André T, Blons H, Mabro M, Chibaudel B, Bachet JB, Tournigand C, et al. Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. Ann Oncol. 2013;24:412–9.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work has been supported by the Russian Scientific Fund (grant number 14-25-00111).

Author information

Authors and Affiliations

  1. Regional Cancer Hospital, Yuzhno-Sakhalinsk, 693010, Russia

    Sergey V. Silkin, Sergey S. Startsev & Marina E. Krasnova

  2. Russian Research Centre for Radiology and Surgical Technologies, St.-Petersburg, 197758, Russia

    Grigory A. Raskin

  3. Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, Pesochny-2, 197758, St.-Petersburg, Russia

    Natalia V. Mitiushkina, Aglaya G. Iyevleva, Anna P. Sokolenko & Evgeny N. Imyanitov

  4. Saint-Petersburg State Pediatric Medical University, St.-Petersburg, 194100, Russia

    Aglaya G. Iyevleva, Anna P. Sokolenko & Evgeny N. Imyanitov

  5. Medical Faculty, Saint Petersburg State University, Saint-Petersburg, 199034, Russia

    Evgeny N. Imyanitov

  6. I.I. Mechnikov North-Western State Medical University, Saint-Petersburg, 191015, Russia

    Evgeny N. Imyanitov

Authors
  1. Sergey V. Silkin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sergey S. Startsev
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marina E. Krasnova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Grigory A. Raskin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Natalia V. Mitiushkina
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Aglaya G. Iyevleva
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Anna P. Sokolenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Evgeny N. Imyanitov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Evgeny N. Imyanitov.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Silkin, S.V., Startsev, S.S., Krasnova, M.E. et al. Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan. J Gastrointest Canc 47, 502–505 (2016). https://doi.org/10.1007/s12029-015-9792-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-015-9792-2

Keywords

Search

Navigation